Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
Total Valuation
Radiopharm Theranostics Limited has a market cap or net worth of AU$72.30M. The enterprise value is AU$20.99M.
Market CapAU$72.30M
Enterprise ValueAU$20.99M
Share Statistics
Radiopharm Theranostics Limited has 2,364,949,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,364,949,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Radiopharm Theranostics Limited’s return on equity (ROE) is -0.82 and return on invested capital (ROIC) is -53.50%.
Return on Equity (ROE)-0.82
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-53.50%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Radiopharm Theranostics Limited is ―. Radiopharm Theranostics Limited’s PEG ratio is 0.01.
PE Ratio―
PS Ratio3.42
PB Ratio1.02
Price to Fair Value1.02
Price to FCF-1.25
Price to Operating Cash Flow-2.29
PEG Ratio0.01
Income Statement
In the last 12 months, Radiopharm Theranostics Limited had revenue of 13.40M and earned -36.70M in profits. Earnings per share was -0.02.
Revenue13.40M
Gross Profit9.81M
Operating Income-38.17M
Pretax Income-38.24M
Net Income-36.70M
EBITDA-31.65M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -36.65M and capital expenditures -4.00, giving a free cash flow of -36.65M billion.
Operating Cash Flow-36.65M
Free Cash Flow-36.65M
Free Cash Flow per Share-0.02
Dividends & Yields
Radiopharm Theranostics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change0.00%
50-Day Moving Average0.03
200-Day Moving Average0.03
Relative Strength Index (RSI)36.53
Average Volume (3m)4.84M
Important Dates
Radiopharm Theranostics Limited upcoming earnings date is Feb 26, 2026, TBA (Not Confirmed).
Last Earnings DateSep 16, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Radiopharm Theranostics Limited as a current ratio of 2.67, with Debt / Equity ratio of 0.00%
Current Ratio2.67
Quick Ratio2.67
Debt to Market Cap0.00
Net Debt to EBITDA0.92
Interest Coverage Ratio-584.59
Taxes
In the past 12 months, Radiopharm Theranostics Limited has paid 103.29K in taxes.
Income Tax103.29K
Effective Tax Rate>-0.01
Enterprise Valuation
Radiopharm Theranostics Limited EV to EBITDA ratio is -0.53, with an EV/FCF ratio of -0.46.
EV to Sales1.25
EV to EBITDA-0.53
EV to Free Cash Flow-0.46
EV to Operating Cash Flow-0.46
Balance Sheet
Radiopharm Theranostics Limited has AU$29.12M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$29.12M billion.
Cash & Marketable SecuritiesAU$29.12M
Total DebtAU$0.00
Net CashAU$29.12M
Net Cash Per ShareAU$0.01
Tangible Book Value Per Share>-AU$0.01
Margins
Gross margin is 73.18%, with operating margin of -284.87%, and net profit margin of -273.90%.
Gross Margin73.18%
Operating Margin-284.87%
Pretax Margin-285.36%
Net Profit Margin-273.90%
EBITDA Margin-236.16%
EBIT Margin-255.53%
Analyst Forecast
The average price target for Radiopharm Theranostics Limited is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast1114.27%
EPS Growth Forecast85.66%